Compare Danaher Corporation (DHR) vs GE Vernova Inc (GEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs GE Vernova Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while GE Vernova Inc trades at $1,004.73 (market cap $266.16B). The key difference: GE Vernova Inc is the larger of the two by market cap, and Danaher Corporation pays the higher dividend (0.74%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and GE Vernova Inc for 36 Days on average.
| DHR | GEV | |
|---|---|---|
Market Cap | $152.87B | $266.16B |
Volume | 5,228,698 | 2,324,165 |
Sector | Health | Industrials |
52-Week High | $242.05 | $1.17K |
52-Week Low | $161.91 | $547.96 |
Typical Hold Time | 69 Days | 36 Days |
Enterprise Value | $175.08B | $255.83B |
Dividend Yield | 0.74% | 0.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
GE Vernova (GEV) trades at $1,004.73, up 0.77% with strong bullish technical momentum. The stock shows exceptional profitability with 23.04% net margins and 91.48% ROE, though valuation appears elevated with P/E of 28.65. Recent Q2 2026 earnings missed expectations, but Q1 and Q4 2025 results significantly beat forecasts. The company secured the first US construction permit for its BWRX-300 SMR, strengthening its nuclear pipeline amid growing AI-driven power demand.
Outlook remains positive with 75.86% analyst buy ratings and $1,270 consensus price target representing 26% upside. Key risks include execution challenges in wind segment and valuation concerns. Strong backlog growth to $176 billion and AI power demand create substantial growth runway, though investors should monitor margin expansion and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →
